PR Newswire·Nov 9, 2026, 9:30 AM ET

Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss

Foundayo reduced breathing interruptions by up to 44% on average in adults with moderate-to-severe OSA & obesity/overweight
Up to 32% of participants achieved remission or mild disease status after 52 weeks of treatment
Foundayo lowered sleep apnea-specific hypoxic burden by up to 55.9% on average, improving oxygen levels during sleep
The drug met primary endpoints in the ATTAIN-OSA Phase 3 clinical program for efficacy & safety
Participants not using PAP therapy saw a 43.8% reduction in AHI events (21.1 fewer events per hour)
Participants using PAP therapy saw a 27.5% reduction in AHI events (18.3 fewer events per hour)
Foundayo treatment resulted in an average weight loss of approximately 28 lbs (11.2% to 11.5%)
Cardiovascular risk factors improved, including a 48.9% average reduction in hsCRP inflammation markers
Systolic blood pressure decreased by an average of 8.6 mmHg in participants not using PAP therapy
Most common adverse events were gastrointestinal, including nausea, diarrhea, & vomiting
Eli Lilly plans to submit Foundayo to the U.S. FDA for moderate-to-severe OSA by the end of 2026
Results from the study were presented at the American Heart Association Scientific Sessions 2026
Findings were simultaneously published in the journal JAMA
Foundayo is a once-daily oral GLP-1 receptor agonist already approved for obesity treatment